Stay updated on Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial page.
Latest updates to the Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial page
- Check5 days agoChange DetectedA banner announces NIH website transition updates and says that some content may use “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI).SummaryDifference1%
- Check12 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%
- Check19 days agoChange DetectedThe ClinicalTrials.gov footer revision label changes from v3.7.0 to v3.7.1, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%
- Check40 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study details, blocking access to the ClinicalTrials.gov entry. This reflects an access restriction rather than a content update to the study record.SummaryDifference21%
- Check48 days agoChange DetectedThe Melanoma label along with related topics and the MedlinePlus Genetics link were removed from the page, reducing disease-focused context and external reference options presented to readers.SummaryDifference0.1%
- Check62 days agoChange DetectedThe study record was updated with new arm descriptions, dosing details, and eligibility language, and an IPD sharing plan was added; a 'Results Posted' notice was also included to reflect recent outcomes.SummaryDifference3%
Stay in the know with updates to Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial page.